Targeting mitochondrial quality control in osteoarthritis with GrpE-like 1-loaded synovial mesenchymal stromal/stem cell small extracellular vesicles.

Abstract

Recent studies have demonstrated that synovial mesenchymal stem cell-derived small extracellular vesicles (EVs) engineered to deliver GrpE-like 1 activated PTEN-induced kinase 1-dependent mitophagy and restored chondrocyte homeostasis. This study revealed that interleukin-1β-challenged chondrocytes exhibited efficient cargo transfer, increased mitophagy signaling with reduced p62 levels, lower oxidative stress, and a shift toward matrix preservation, characterized by higher collagen II and aggrecan levels, and lower matrix metallopeptidase 13 and ADAM metallopeptidase with thrombospondin type 1 motif 5 levels. In a rat knee osteoarthritis model, intra-articular dosing preserved cartilage architecture and improved histological scores. Collectively, these findings suggest that EV-based delivery of mitochondrial regulators is a plausible disease-modifying strategy, rather than purely symptomatic care. Building on this evidence, this editorial distills key advances and outlines near-term research and translational priorities, including standardized EV characterization, pharmacokinetics, dosing, safety, and manufacturability. The suitability of GrpE-like 1-loaded small EVs for early-stage osteoarthritis was also evaluated.